Belgium· BE-AMP-SAM220884-00

Eldepryl 10 mg

A selegiline product containing selegiline hydrochloride, registered in Belgium by Orion. The same ATC class is registered in 14 of our 19 countries.

ATC N04BD01

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedEldepryl 10 mgATCN04BD01REGISTER NO.BE-AMP-SAM220884-00PACKS LISTED2CHECKEDSeptember 26, 2026

Where it is registered

Selegiline is registered in 14 of 19 countries.

Countries holding a registration under ATC N04BD01 (selegiline), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 8 of them publish a price we can compare per daily dose

Selegiline · ATC N04BD01

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Italyprice
  • Japan
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of selegiline costs, country by country.

Normalised to the WHO defined daily dose (5 mg), the median price runs from $0.24 in Italy to $0.62 in France — a ×2.5 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Selegiline · price per daily dose (5 mg)

USD · FX 28 Sept 2026

  • FR France$0.62
  • IT Italy$0.24
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Selegiline Hydrochloride
Manufacturer
Orion
Country
Belgium (BE)
ATC code
N04BD01
ATC class
Selegiline
Defined daily dose
5 mg, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

1 priced
  • be_apb
    1691138
    EUR 46.27
  • be_apb
    0768770

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

187 interactions on record for selegiline.

Graded by severity as the source publishes them — 35 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Selegiline · interactions on record

187 records

  • 35 severe
  • 115 moderate
  • 1 minor
  • 21 info

Most severe, free to view

  • IsomethepteneA03AX10severe
  • OpiumA07DA02severe
  • PhentermineA08AA01severe
  • FenfluramineA08AA02severe

15 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Selegiline in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All selegiline products

Authorised across Europe · EMA

The same active substance is authorised in 18 EEA countries. Names it is sold under:

  • Bulgaria · Jamax, Селегос
  • Cyprus · Selegos, Selex
  • Germany · Selegilin Neuraxpharm
  • Denmark · Eldepryl
  • Spain · Plurimen
  • Finland · Eldepryl
  • France · Deprenyl
  • United Kingdom (Northern Ireland) · Eldepryl, Selegiline Hydrochloride Activase Pharmaceuticals
  • Greece · Feliselin
  • Ireland · Eldepryl
  • Italy · Jumex, Selecom
  • Luxembourg · Eldepryl
  • Latvia · Eldepryl
  • Norway · Eldepryl
  • Poland · Selgres
  • Portugal · Selegilina Generis
  • Romania · Selegos
  • Sweden · Eldepryl

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/3b26d187-0512-4a12-8b75-4dae65ae49bd
GET /v1/drugs/3b26d187-0512-4a12-8b75-4dae65ae49bd?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Eldepryl 10 mg",
  "name_fr": "Eldepryl 10 mg",
  "name_nl": "Eldepryl 10 mg",
  "amp_code": "SAM220884-00",
  "strengths": [
    "10.0000",
    "20.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Selegiline Hydrochloride",
    "Ethanol",
    "Mannitol"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Selegiline",
  "authorisation_numbers": [
    "BE220884"
  ]
}

See everything about selegiline.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.